Rheumatoid arthritis (disorder)
PEAC: Pathobiology of Early Arthritis Cohort
Year Started: 2008
Prospective, observational study in patients with early symptomatic inflammatory arthritis (http://www.peac-mrc.mds.qmul.ac.uk/). Biological samples (synovial tissue & fluids) are collected at two timepoints - Baseline & Follow-up (6 month), please note figures for baseline samples are represented (6 month sample availability on request). Demographic & clinical data is available & collected at 5 timepoints over a 1-year follow-up period (Baseline, 3, 6, 9 & 12 months). Current recruitment status for Rheumatoid Arthritis cohort is 214 patients (1st April 2019).
- Access:
- Closed to access
- Type:
- Cohort
- Status:
- In progress
- Consent restrictions:
- Xenograft restriction
| Associated Data Type | Procurement Timeframe |
|---|---|
| Biomarker datasets | 0 - 3 months |
| Clinical records | 0 - 3 months |
| Followup records | 0 - 3 months |
| Freezer temperature logs | 0 - 3 months |
| Genomic datasets | 0 - 3 months |
| Imaging data | 0 - 3 months |
| Pathology records | 0 - 3 months |
| Physiological/biochemical measurements | 0 - 3 months |
| Quality indicators | 0 - 3 months |
| Treatment records | 0 - 3 months |
| Donor Ethnicity | 0 - 3 months |
Unknown
Data not recorded
101 - 500 donors
| Material Type | Extraction Procedure | Storage Temperature | Preservation Type | Macroscopic Assessment | % of Sample Set |
|---|---|---|---|---|---|
| Peripheral blood mononuclear cells (PBMC) | Liquid nitrogen liquid phase | N/A | Affected | 75% -99% | |
| Plasma | -60°C to -85°C | N/A | Affected | 75% -99% | |
| RNA | -60°C to -85°C | N/A | Affected | 51 - 75% | |
| Serum | -60°C to -85°C | N/A | Affected | 75% -99% | |
| Tissue specimen | Surgical procedure (procedure) | RT | Paraffin | Affected | 75% -99% |
| Urine | -60°C to -85°C | N/A | Affected | 75% -99% |
Psoriatic arthritis (disorder)
PEAC: Pathobiology of Early Arthritis Cohort
Year Started: 2008
Prospective, observational study in patients with early symptomatic inflammatory arthritis (http://www.peac-mrc.mds.qmul.ac.uk/). Biological samples (synovial tissue & fluids) are collected at two timepoints - Baseline & Follow-up (6 month), please note figures for baseline samples are represented (6 month sample availability on request). Demographic & clinical data is available & collected at 5 timepoints over a 1-year follow-up period (Baseline, 3, 6, 9 & 12 months). Current recruitment status for Psoriatic Arthritis cohort is 44 patients (1st April 2019).
- Access:
- Closed to access
- Type:
- Cohort
- Status:
- In progress
- Consent restrictions:
- Xenograft restriction
| Associated Data Type | Procurement Timeframe |
|---|---|
| Biomarker datasets | 0 - 3 months |
| Clinical records | 0 - 3 months |
| Followup records | 0 - 3 months |
| Freezer temperature logs | 0 - 3 months |
| Genomic datasets | 0 - 3 months |
| Imaging data | 0 - 3 months |
| Pathology records | 0 - 3 months |
| Physiological/biochemical measurements | 0 - 3 months |
| Quality indicators | 0 - 3 months |
| Treatment records | 0 - 3 months |
| Donor Ethnicity | 0 - 3 months |
Unknown
Data not recorded
11 - 100 donors
| Material Type | Extraction Procedure | Storage Temperature | Preservation Type | Macroscopic Assessment | % of Sample Set |
|---|---|---|---|---|---|
| Peripheral blood mononuclear cells (PBMC) | Liquid nitrogen liquid phase | N/A | Affected | 75% -99% | |
| Plasma | -60°C to -85°C | N/A | Affected | 75% -99% | |
| RNA | -60°C to -85°C | N/A | Affected | 51 - 75% | |
| Serum | -60°C to -85°C | N/A | Affected | 75% -99% | |
| Tissue specimen | Surgical procedure (procedure) | RT | Paraffin | Affected | 75% -99% |
| Urine | -60°C to -85°C | N/A | Affected | 75% -99% |
Undifferentiated inflammatory arthritis (disorder)
PEAC: Pathobiology of Early Arthritis Cohort
Year Started: 2008
Prospective, observational study in patients with early symptomatic inflammatory arthritis (http://www.peac-mrc.mds.qmul.ac.uk/). Biological samples (synovial tissue & fluids) are collected at two timepoints - Baseline & Follow-up (6 month), please note figures for baseline samples are represented (6 month sample availability on request). Demographic & clinical data is available & collected at 5 timepoints over a 1-year follow-up period (Baseline, 3, 6, 9 & 12 months). Current recruitment status for the Undifferentiated/Non-Inflammatory Arthritis cohort is 65 patients (1st April 2019).
- Access:
- Closed to access
- Type:
- Cohort
- Status:
- In progress
- Consent restrictions:
- Xenograft restriction
| Associated Data Type | Procurement Timeframe |
|---|---|
| Biomarker datasets | 0 - 3 months |
| Clinical records | 0 - 3 months |
| Followup records | 0 - 3 months |
| Freezer temperature logs | 0 - 3 months |
| Genomic datasets | 0 - 3 months |
| Imaging data | 0 - 3 months |
| Pathology records | 0 - 3 months |
| Quality indicators | 0 - 3 months |
| Treatment records | 0 - 3 months |
| Donor Ethnicity | 0 - 3 months |
Unknown
Data not recorded
11 - 100 donors
| Material Type | Extraction Procedure | Storage Temperature | Preservation Type | Macroscopic Assessment | % of Sample Set |
|---|---|---|---|---|---|
| Peripheral blood mononuclear cells (PBMC) | Liquid nitrogen liquid phase | N/A | Affected | 75% -99% | |
| Plasma | -60°C to -85°C | N/A | Affected | 75% -99% | |
| RNA | -60°C to -85°C | N/A | Affected | 51 - 75% | |
| Serum | -60°C to -85°C | N/A | Affected | 75% -99% | |
| Tissue specimen | Surgical procedure (procedure) | RT | Paraffin | Affected | 75% -99% |
| Urine | -60°C to -85°C | N/A | Affected | 75% -99% |
Rheumatoid arthritis (disorder)
R4-RA: A Randomised, open labelled study in anti-TNFa inadequate responders to investigate the mechanisms for Response - Resistance to Rituximab versus Tocilizumab in RA
Year Started: 2013
Open-label, randomised controlled clinical trial, multi-centre, multi-country, Phase IV study (http://www.r4ra-nihr.whri.qmul.ac.uk/). Biological samples (synovial tissue & fluids) are collected at multiple timepoints (details available on request), please note figures for baseline samples are represented (availability of samples from other timepoints on request). Demographic & clinical data is available & collected at multiple timepoints over a 2-year follow-up period. Recruitment status for this study is 164 patients.
- Access:
- Closed to access
- Type:
- Clinical Trial
- Status:
- Completed
- Consent restrictions:
- Xenograft restriction
| Associated Data Type | Procurement Timeframe |
|---|---|
| Biomarker datasets | 0 - 3 months |
| Clinical records | 0 - 3 months |
| Followup records | 0 - 3 months |
| Freezer temperature logs | 0 - 3 months |
| Genomic datasets | 0 - 3 months |
| Imaging data | 0 - 3 months |
| Pathology records | 0 - 3 months |
| Quality indicators | 0 - 3 months |
| Treatment records | 0 - 3 months |
| Donor Ethnicity | 0 - 3 months |
Unknown
Data not recorded
101 - 500 donors
| Material Type | Extraction Procedure | Storage Temperature | Preservation Type | Macroscopic Assessment | % of Sample Set |
|---|---|---|---|---|---|
| Peripheral blood mononuclear cells (PBMC) | Liquid nitrogen liquid phase | N/A | Affected | 75% -99% | |
| Plasma | -60°C to -85°C | N/A | Affected | 75% -99% | |
| RNA | -60°C to -85°C | N/A | Affected | 75% -99% | |
| Serum | -60°C to -85°C | N/A | Affected | 75% -99% | |
| Tissue specimen | Surgical procedure (procedure) | RT | Paraffin | Affected | 75% -99% |
Rheumatoid arthritis (disorder)
STRAP: Stratification of Biologic Therapies for RA by Pathobiology. A randomised, open-labelled biopsy-driven stratification trial in DMARD inadequate responder patients randomised to Etanercept, Tocilizumab or Rituximab.
Year Started: 2015
Open-label, randomised controlled clinical trial, multi-centre, multi-country, Phase III study (http://www.matura-mrc.whri.qmul.ac.uk/). Biological samples (synovial tissue & fluids) are collected at multiple timepoints (details available on request), please note figures for baseline samples are represented (availability of samples from other timepoints on request). Demographic & clinical data is available & collected at multiple timepoints over a 2-year follow-up period. Current recruitment status for this study is 200 patients (1st April 2019).
- Access:
- Closed to access
- Type:
- Clinical Trial
- Status:
- In progress
- Consent restrictions:
- Xenograft restriction
| Associated Data Type | Procurement Timeframe |
|---|---|
| Biomarker datasets | 0 - 3 months |
| Clinical records | 0 - 3 months |
| Followup records | 0 - 3 months |
| Freezer temperature logs | 0 - 3 months |
| Genomic datasets | 0 - 3 months |
| Imaging data | 0 - 3 months |
| Pathology records | 0 - 3 months |
| Physiological/biochemical measurements | 0 - 3 months |
| Quality indicators | 0 - 3 months |
| Treatment records | 0 - 3 months |
| Donor Ethnicity | 0 - 3 months |
Unknown
Data not recorded
101 - 500 donors
| Material Type | Extraction Procedure | Storage Temperature | Preservation Type | Macroscopic Assessment | % of Sample Set |
|---|---|---|---|---|---|
| Peripheral blood mononuclear cells (PBMC) | Liquid nitrogen liquid phase | N/A | Affected | 75% -99% | |
| Plasma | -60°C to -85°C | N/A | Affected | 75% -99% | |
| RNA | -60°C to -85°C | N/A | Affected | 75% -99% | |
| Serum | -60°C to -85°C | N/A | Affected | 75% -99% | |
| Tissue specimen | Surgical procedure (procedure) | RT | Paraffin | Affected | 75% -99% |